Drug intelligence / Profile preview

BI 3000202

Development stage: Phase 2
Lead developer: Boehringer
Modality: Small Molecules
Administration: Oral

Overview

BI 3000202 is an investigational small molecule drug developed by Boehringer Ingelheim. It is currently in early clinical development, with completed Phase 1 trials focused on evaluating its safety, tolerability, and pharmacokinetics in healthy volunteers. The mechanism of action for BI 3000202 has not been disclosed and remains unknown. Clinical studies have also explored the effect of the drug on the metabolism of midazolam and its tolerability in people with selected type I interferonopathies[1][2][4][5].

Targets

Cyclic GMP–AMP synthase

Beyond the preview

Go deeper on BI 3000202.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BI 3000202.

Explore the full profile